Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's di...
Investigated for the treatment of schizophrenia and schizoaffective disorder.
Reviva site, Richardson, Texas, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.